Catalytically inactive anthrax toxin(s) are potential prophylactic agents

Vaccine

Volumn 25, Issue 50, 2007, Pages 8410-8419

  Gupta, Megha ^a   Alam, Sheeba ^a   Bhatnagar, Rakesh ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Active site mutants; Edema factor; Lethal factor

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; ANTIGEN; EDEMA FACTOR; EDEMA FACTOR H351A; LETHAL FACTOR E687A; MUTANT PROTEIN; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; CATALYSIS; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; LETHAL GENE; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CATALYSIS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; MACROPHAGES; MICE; MUTATION;

EID: 36248976620     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.063     Document Type: Article

References (45)

1. Collier R.J., and Young J.A. Anthrax toxin. Annu Rev Cell Dev Biol 19 (2003) 45-70
2. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280 5364 (1998) 734-737
3. Vitale G., Pellizzari R., Recchi C., Napolitani G., Mock M., and Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun 248 3 (1998) 706-711
4. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 79 10 (1982) 3162-3166
5. Culley N.C., Pinson D.M., Chakrabarty A., Mayo M.S., and Levine S.M. Pathophysiological manifestations in mice exposed to anthrax lethal toxin. Infect Immun 73 10 (2005) 7006-7010
6. Firoved A.M., Miller G.F., Moayeri M., Kakkar R., Shen Y., Wiggins J.F., et al. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality. Am J Pathol 167 5 (2005) 1309-1320
7. Moayeri M., Haines D., Young H.A., and Leppla S.H. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest 112 5 (2003) 670-682
8. Hoover D.L., Friedlander A.M., Rogers L.C., Yoon I.K., Warren R.L., and Cross A.S. Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun 62 10 (1994) 4432-4439
9. Comer J.E., Chopra A.K., Peterson W.J., and Konig R. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect Immun 73 12 (2005) 8275-8281
10. Tournier J.N., Quesnel-Hellmann A., Mathieu J., Montecucco C., Tang W.J., Mock M., et al. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J Immunol 174 8 (2005) 4934-4941
11. Baldari C.T., Tonello F., Paccani S.R., and Montecucco C. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol 27 9 (2006) 434-440
12. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 32 (2001) 4768-4773
13. Little S.F., Ivins B.E., Fellows P.F., and Friedlander A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 65 12 (1997) 5171-5175
14. Belton F.C., and Strange R.E. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Br J Exp Pathol 35 2 (1954) 144-152
15. Friedlander A.M., Pittman P.R., and Parker G.W. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 282 22 (1999) 2104-2106
16. In: Joellenbeck L.M., Zwanziger L.L., Durch J.S., and Strom B.L. (Eds). The anthrax vaccine. is it safe? does it work? (2002), National Academy Press, Washington DC, USA 265
17. Pezard C., Weber M., Sirard J.C., Berche P., and Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun 63 4 (1995) 1369-1372
18. Quesnel-Hellmann A., Cleret A., Vidal D.R., and Tournier J.N. Evidence for adjuvanticity of anthrax edema toxin. Vaccine 24 6 (2006) 699-702
19. Zeng M., Xu Q., Hesek E.D., and Pichichero M.E. N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 24 5 (2005) 662-670
20. Price B.M., Liner A.L., Park S., Leppla S.H., Mateczun A., and Galloway D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69 7 (2001) 4509-4515
21. Brossier F., Weber-Levy M., Mock M., and Sirard J.C. Role of toxin functional domains in anthrax pathogenesis. Infect Immun 68 4 (2000) 1781-1786
22. Lacy D.B., Mourez M., Fouassier A., and Collier R.J. Mapping the anthrax protective antigen binding site on the lethal and edema factors. J Biol Chem 277 4 (2002) 3006-3010
23. Liang X., Young J.J., Boone S.A., Waugh D.S., and Duesbery N.S. Involvement of domain II in toxicity of anthrax lethal factor. J Biol Chem 279 50 (2004) 52473-52478
24. Kumar P., Ahuja N., and Bhatnagar R. Purification of anthrax edema factor from Escherichia coli and identification of residues required for binding to anthrax protective antigen. Infect Immun 69 10 (2001) 6532-6536
25. Gupta P., Singh A., Chauhan V., and Bhatnagar R. Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis. Biochem Biophys Res Commun 280 1 (2001) 158-163
26. Tonello F., Naletto L., Romanello V., Dal Molin F., and Montecucco C. Tyrosine-728 and glutamic acid-735 are essential for the metalloproteolytic activity of the lethal factor of Bacillus anthracis. Biochem Biophys Res Commun 313 3 (2004) 496-502
27. Hammond S.E., and Hanna P.C. Lethal factor active-site mutations affect catalytic activity in vitro. Infect Immun 66 5 (1998) 2374-2378
28. Gupta M., Alam S., and Bhatnagar R. Kinetic characterization and ligand binding studies of His351 mutants of Bacillus anthracis adenylate cyclase. Arch Biochem Biophys 446 1 (2006) 28-34
29. Shen Y., Zhukovskaya N.L., Guo Q., Florián J., and Tang W.J. Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J 24 5 (2005) 929-941
30. Klimpel K.R., Arora N., and Leppla S.H. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 13 6 (1994) 1093-1100
31. Ahuja N., Kumar P., and Bhatnagar R. Rapid purification of recombinant anthrax-protective antigen under nondenaturing conditions. Biochem Biophys Res Commun 286 1 (2001) 6-11
32. Zhao J., Milne J.C., and Collier R.J. Effect of anthrax toxin's lethal factor on ion channels formed by the protective antigen. J Biol Chem 270 31 (1995) 18626-18630
33. Bhatnagar R., Ahuja N., Goila R., Batra S., Waheed S.M., and Gupta P. Activation of phospholipase C and protein kinase C is required for expression of anthrax lethal toxin cytotoxicity in J774A.1 cells. Cell Signal 11 2 (1999) 111-116
34. McConnell M.J., Hanna P.C., and Imperiale M.J. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect Immun 74 2 (2006) 1009-1015
35. Pellizzari R., Guidi-Rontani C., Vitale G., Mock M., and Montecucco C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett 462 1-2 (1999) 199-204
36. Paccani S.R., Tonello F., Ghittoni R., Natale M., Muraro L., D'Elios M.M., et al. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med 201 3 (2005) 325-331
37. Stanley J.L., and Smith H. The three factors of anthrax toxin: their immunogenicity and lack of demonstrable enzymic activity. J Gen Microbiol 31 (1963) 329-337
38. Ivins B.E., and Welkos S.L. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 4 1 (1988) 12-19
39. Mahlandt B.G., Klein F., Lincoln R.E., Haines B.W., Jones W.I., and Friedman R.H. Immunologic studies of anthrax. IV. Evaluation of the immunogenicity of three components of anthrax toxin. J Immunol 96 4 (1966) 727-733
40. Singh Y., Ivins B.E., and Leppla S.H. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect Immun 66 7 (1998) 3447-3448
41. Spyres L.M., Daniel J., Hensley A., Qa'Dan M., Ortiz-Leduc W., and Ballard J.D. Mutational analysis of the enzymatic domain of Clostridium difficile toxin B reveals novel inhibitors of the wild-type toxin. Infect Immun 71 6 (2003) 3294-3301
42. Ahuja N., Kumar P., Alam S., Gupta M., and Bhatnagar R. Deletion mutants of protective antigen that inhibit anthrax toxin both in vitro and in vivo. Biochem Biophys Res Commun 307 3 (2003) 446-450
43. Duverger A., Jackson R.J., van Ginkel F.W., Fischer R., Tafaro A., Leppla S.H., et al. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 176 3 (2006) 1776-1783
44. Peachman K.K., Rao M., Alving C.R., Burge R., Leppla S.H., Rao V.B., et al. Correlation between lethal toxin-neutralizing antibody titres and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect Immun 74 1 (2006) 794-797
45. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69 5 (2001) 2888-2893